A JNK inhibitor SP600125 induces defective cytokinesis and enlargement in P19 embryonal carcinoma cells

While analyzing the role of c‐Jun NH2‐terminal kinase (JNK) in neurogenesis in P19 embryonal carcinoma cells, we noticed that treatment with SP600125, a JNK inhibitor, increased the cell size markedly. SP600125‐induced enlargement of P19 cells was time‐ and dose‐dependent. The increased cell size in...

Full description

Saved in:
Bibliographic Details
Published in:Cell biochemistry and function 2009-10, Vol.27 (7), p.468-472
Main Authors: Nakaya, Kohei, Ooishi, Ryo, Funaba, Masayuki, Murakami, Masaru
Format: Article
Language:English
Subjects:
Animals
Anthracenes - pharmacology
c-Jun NH2-terminal kinase
Cell Enlargement - drug effects
Cell Proliferation - drug effects
Cell Shape - drug effects
cell size
Cytokinesis - drug effects
Cytokinesis - genetics
Demecolcine - pharmacology
Embryonal Carcinoma Stem Cells - enzymology
Embryonal Carcinoma Stem Cells - pathology
endoreduplication
Gene Expression Regulation, Neoplastic - drug effects
Hep G2 Cells
Humans
JNK Mitogen-Activated Protein Kinases - antagonists & inhibitors
Mice
P19
Protein Kinase Inhibitors - pharmacology
SP600125
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:While analyzing the role of c‐Jun NH2‐terminal kinase (JNK) in neurogenesis in P19 embryonal carcinoma cells, we noticed that treatment with SP600125, a JNK inhibitor, increased the cell size markedly. SP600125‐induced enlargement of P19 cells was time‐ and dose‐dependent. The increased cell size in response to SP600125 was also detected in B6mt‐1 embryonic stem cells. SP600125 treatment inhibited cell growth and increased DNA contents, indicating the inhibition of cell proliferation resulting from endoreduplication. Concurrently, the gene expression of p21, a regulator of G2/M arrest as well as G1 arrest, was increased in cells treated with SP600125. The increased cell size in response to SP600125 was detected even in P19 cells treated with colcemide, an inhibitor of cell cycle progression at the metaphase. The present study suggests that treatment with SP600125 progresses the cell cycle, skipping cytokinesis in P19 cells. Copyright © 2009 John Wiley & Sons, Ltd.
ISSN:0263-6484
1099-0844
DOI:10.1002/cbf.1597